| Literature DB >> 23234271 |
Etzer Darout1, Ralph P Robinson, Kim F McClure, Matthew Corbett, Bryan Li, Andrei Shavnya, Melissa P Andrews, Christopher S Jones, Qifang Li, Martha L Minich, Vincent Mascitti, Cristiano R W Guimarães, Michael J Munchhof, Kevin B Bahnck, Cuiman Cai, David A Price, Spiros Liras, Paul D Bonin, Peter Cornelius, Ruduan Wang, Victoria Bagdasarian, Colleen P Sobota, Sam Hornby, Victoria M Masterson, Reena M Joseph, Amit S Kalgutkar, Yue Chen.
Abstract
A series of GPR119 agonists based on a 2,6-diazatricyclo[3.3.1.1∼3,7∼]decane ring system is described. Also provided is a detailed account of the development of a multigram scale synthesis of the diazatricyclic ring system, which was achieved using a Hofmann-Löffler-Freytag reaction as the key step. The basis for the use of this complex framework lies in an attempt to constrain one end of the molecule in the "agonist conformation" as was previously described for 3-oxa-7-aza-bicyclo[3.3.1]nonanes. Optimization of carbamate analogues of the diazatricylic compounds led to the identification of 32i as a potent agonist of the GPR119 receptor with low unbound human liver microsomal clearance. The use of an agonist response weighted ligand lipophilic efficiency (LLE) termed AgLLE is discussed along with the issues of applying efficiency measures to agonist programs. Ultimately, solubility limited absorption and poor exposure reduced further interest in these molecules.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23234271 DOI: 10.1021/jm301626p
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446